{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:45:24Z","timestamp":1788277524652,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ijcha.2025.101653","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T01:23:37Z","timestamp":1742693017000},"page":"101653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on hemoglobin, B-type natriuretic peptide, and renal function in anemic heart failure patients: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"58","author":[{"given":"Hidekatsu","family":"Fukuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcha.2025.101653_b0005","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of heart failure: a contemporary perspective","volume":"128","author":"Roger","year":"2021","journal-title":"Circ. Res."},{"issue":"11","key":"10.1016\/j.ijcha.2025.101653_b0010","first-page":"35","article-title":"Anemia of cardiorenal syndrome","volume":"2021","author":"McCullough","year":"2011","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.ijcha.2025.101653_b0015","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/CIRCULATIONAHA.105.583666","article-title":"Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options","volume":"113","author":"Tang","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2025.101653_b0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial","volume":"51","author":"Okonko","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2025.101653_b0025","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2025.101653_b0030","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.ijcard.2013.04.181","article-title":"IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia","volume":"168","author":"Beck-da-Silva","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcha.2025.101653_b0035","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2025.101653_b0040","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ejhf.473","article-title":"Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials","volume":"18","author":"Jankowska","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcha.2025.101653_b0045","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2025.101653_b0050","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/eurheartj\/ehm328","article-title":"Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia","volume":"28","author":"van Veldhuisen","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2025.101653_b0055","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/CIRCULATIONAHA.107.698514","article-title":"Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia","volume":"117","author":"Ghali","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2025.101653_b0060","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijcard.2016.04.187","article-title":"The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: a meta-analysis of randomized clinical trials","volume":"218","author":"Kang","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcha.2025.101653_b0065","first-page":"247","article-title":"Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis","volume":"12","author":"Zhang","year":"2016","journal-title":"Postepy Kardiol Interwencyjnej"},{"key":"10.1016\/j.ijcha.2025.101653_b0070","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD","volume":"69","author":"Gupta","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ijcha.2025.101653_b0075","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00380-022-02181-1","article-title":"Initial experience of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with heart failure and renal anemia","volume":"38","author":"Nakamura","year":"2023","journal-title":"Heart Vessels"},{"key":"10.1016\/j.ijcha.2025.101653_b0080","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/medicina60010084","article-title":"Efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitor on clinical parameters in patients with heart failure","volume":"60","author":"Yazaki","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.ijcha.2025.101653_b0085","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13104-024-06726-7","article-title":"Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia","volume":"17","author":"Kambara","year":"2024","journal-title":"BMC. Res. Notes"},{"key":"10.1016\/j.ijcha.2025.101653_b0090","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13102764","volume":"13","author":"Sezai","year":"2024","journal-title":"J. Clin. Med."},{"issue":"264\u2013269","key":"10.1016\/j.ijcha.2025.101653_b0095","doi-asserted-by":"crossref","first-page":"W264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcha.2025.101653_b0100","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"key":"10.1016\/j.ijcha.2025.101653_b0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.ijcha.2025.101653_b0110","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1007\/s12325-023-02433-0","article-title":"Safety of roxadustat versus erythropoiesis-stimulating agents in patients with anemia of non-dialysis-dependent or incident-to-dialysis chronic kidney disease: pooled analysis of four phase 3 studies","volume":"40","author":"Barratt","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ijcha.2025.101653_b0115","doi-asserted-by":"crossref","unstructured":"JPT. Higgins, J. Thomas, J. Chandler et al. Cochrane Handbook for Systematic Reviews of Interventions. 2019.","DOI":"10.1002\/9781119536604"},{"key":"10.1016\/j.ijcha.2025.101653_b0120","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2025.101653_b0125","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ijcha.2025.101653_b0130","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2025.101653_b0135","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2025.101653_b0140","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2025.101653_b0145","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2025.101653_b0150","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2025.101653_b0155","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2025.101653_b0160","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1002\/ehf2.14109","article-title":"Daprodustat for anaemia in patients with heart failure and chronic kidney disease: a randomized controlled study","volume":"9","author":"Iso","year":"2022","journal-title":"ESC Heart Fail"}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906725000569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906725000569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T15:37:45Z","timestamp":1747928265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906725000569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":32,"alternative-id":["S2352906725000569"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2025.101653","relation":{},"ISSN":["2352-9067"],"issn-type":[{"value":"2352-9067","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on hemoglobin, B-type natriuretic peptide, and renal function in anemic heart failure patients: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2025.101653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101653"}}